Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (271-280 of 580) with videos related to

Pageof 58
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinibKarl Lewis, Axel Hauschild, James Larkin, et al.
Travel Medicine and Infectious Disease|November 5, 2023
Challenges in the management of high-altitude illnesses and emergencies in Bhutan and NepalThinley Dorji, Sweta Giri, Ugyen Tshering, et al.
JAMA Oncology|August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical TrialsAxel Hauschild, James Larkin, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)Wenxin Xu, Mäneka Puligandla, Brian Halbert, et al.
Heart and Vessels|January 1, 1988
In vitro studies of isolated supported human heartsD Burkhoff, J T Flaherty, D T Yue, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|February 4, 2005
Case study: the internet as a developmental tool in an adolescent boy with psychosisMelita L Daley, Daniel F Becker, Lois T Flaherty, et al.
Journal of Translational Medicine|August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trialsPaolo A Ascierto, Antoni Ribas, James Larkin, et al.
Journal of Cellular Biochemistry|August 30, 2019
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancerThomas D Wright, Christopher Raybuck, Akshita Bhatt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Molecular Cancer Therapeutics|April 26, 2013
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanomaRoberto A Salas Fragomeni, Hye Won Chung, Yosef Landesman, et al.
Pageof 58

Showing results (271-280 of 580) with videos related to

Sort By:
Pageof 58
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinibKarl Lewis, Axel Hauschild, James Larkin, et al.
Travel Medicine and Infectious Disease|November 5, 2023
Challenges in the management of high-altitude illnesses and emergencies in Bhutan and NepalThinley Dorji, Sweta Giri, Ugyen Tshering, et al.
JAMA Oncology|August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical TrialsAxel Hauschild, James Larkin, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)Wenxin Xu, Mäneka Puligandla, Brian Halbert, et al.
Heart and Vessels|January 1, 1988
In vitro studies of isolated supported human heartsD Burkhoff, J T Flaherty, D T Yue, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|February 4, 2005
Case study: the internet as a developmental tool in an adolescent boy with psychosisMelita L Daley, Daniel F Becker, Lois T Flaherty, et al.
Journal of Translational Medicine|August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trialsPaolo A Ascierto, Antoni Ribas, James Larkin, et al.
Journal of Cellular Biochemistry|August 30, 2019
Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancerThomas D Wright, Christopher Raybuck, Akshita Bhatt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Molecular Cancer Therapeutics|April 26, 2013
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanomaRoberto A Salas Fragomeni, Hye Won Chung, Yosef Landesman, et al.
Pageof 58